AbbVie to Showcase Breadth of Oncology Portfolio and Pipeline at the 2021 ASCO and EHA Annual Congresses
ABBVie will present results from 43 abstracts across 12 types of cancer during the upcoming virtual American Society of Clinical Oncology Annual Meeting and the virtual European Hematology Association congress . “We are advancing discovery and innovation to improve on the standards of care for blood cancer treatment,” said Mohamed Zaki M.D., Ph.D., vice president and global head of oncology development, AbbVie. “We …
– ABBVie (NYSE: ABBV) will present results from 43 abstracts across 12 types of cancer during the upcoming virtual American Society of Clinical Oncology (ASCO) Annual Meeting ( June 4-8 ) and the virtual European Hematology Association (EHA) congress ( June 9-17 ).
Celyad Oncology SA: Celyad Oncology Announces First Quarter 2021 Financial Results and Recent Business Highlights
Enrollment continues in second dose cohort of Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory multiple myeloma (r/r MM); additional proof-of-concept data anticipated in second quarter 2021.
Expansion segment of Phase 1 alloSHRINK trial evaluating allogeneic CYAD-101 administered concurrently with preconditioning chemotherapy for the treatment of advanced metastatic colorectal cancer (mCRC) ongoing; preliminary data expected in mid-2021.
Phase 1b KEYNOTE-B79 trial evaluating CYAD-101 with KEYTRUDA in patients with microsatellite stable mCRC expected to be initiated in first half of 2021.
Regulatory News:
email article
The advent of next-generation proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies over the last decade has revolutionized the way patients with multiple myeloma are managed.
However, the disease remains challenging, as relapse and disease progression remain common, even after complete remission. Myeloma often mutates and becomes more resistant to subsequent lines of therapy, leading to shorter responses and remissions.
Why CAR T-Cell Therapy?
Chimeric antigen receptor (CAR) T-cell therapy is one of the latest available therapeutic strategies in relapsed or refractory multiple myeloma (RRMM). Why is this a promising approach? The bigger question is why CAR T-cell therapy is a good strategy for blood cancer to begin with, said Saad Usmani, MD, of the Levine Cancer Institute in Charlotte, North Carolina.
Family Caregiver Burnout: This Author s Personal Experience And Advice forbes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbes.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
WASHINGTON, March 11, 2021 /PRNewswire/ Roxana Muzzammel, founder of Grassroots-Fund, will host a special virtual event with the Leukemia and Lymphoma Society (LLS) called: Remembrance, Celebration, & a Hope for a Cure. This event will take place online on Friday, March 19
th at 7:30PM EST and aims to inform those in the greater Washington DC area of the medical research advancement within the blood cancer field, as well as share the stories of cancer survivors. Ria Freydberg (Executive Director) and Heather Burneson (Senior Manager of Patient and Community Outreach) for the Mid-Atlantic Region of LLS will speak on the progress with blood cancer research. There will also be remarks and inspirational stories from blood cancer survivors Kareem Abdul-Jabbar (Former NBA Player), Loriana Hernandez-Aldama (Emmy Award Winning Journalist/Former News Anchor), Kathleen Rosendall, Karter (2021 LLS Boy of the Year), and Ella (2021 LLS Girl of the Year)